Investment Thesis
Apogee Therapeutics is a pre-revenue biopharmaceutical company with severe cash burn and negative profitability metrics that indicate an unsustainable business model. With operating losses of $285.6M and free cash flow of -$232.6M, the company is consuming capital at an alarming rate despite having only $131.5M in cash reserves. The lack of any revenue generation combined with mounting losses raises fundamental questions about the company's path to profitability and viability.
APGE Strengths
- Strong liquidity position with current ratio of 26.57x and $131.5M cash reserves
- Moderate debt load with total liabilities of only $33.3M relative to asset base
- Significant insider activity with 13 Form 4 filings in last 90 days suggesting management confidence
APGE Risks
- No revenue generation with operating losses of $285.6M indicating pre-commercial stage company
- Negative free cash flow of -$232.6M means cash runway of approximately 7 months at current burn rate
- Highly negative ROA of -27.3% reflects severe asset inefficiency and value destruction
- Net loss of $255.8M with no path to profitability demonstrated in available financial data
Key Metrics to Watch
- Time to positive operating cash flow and path to revenue generation
- Cash burn rate and remaining cash runway duration
- Clinical trial progress and regulatory milestones for pipeline candidates
APGE Financial Metrics
APGE Profitability Ratios
APGE Balance Sheet & Liquidity
APGE 5-Year Financial Trend
5-Year Trend Summary: Apogee Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.36 indicates the company is currently unprofitable.
APGE Growth Metrics (YoY)
APGE Capital Allocation
APGE SEC Filings
Access official SEC EDGAR filings for Apogee Therapeutics, Inc. (CIK: 0001974640)